ISSN NO. 2320 - 7418
Track your Article
To check the publication status of your article.Click Here
Get our newsletter right into your inbox by subscribing us.
ON CLINICAL ADVERSE DRUG REACTION OF ANTI-NEOPLASTIC AGENTS
Joel Thomas*1, Joshin Sara Cherian1, Feba Susan Varghese1, Shelina Hephzibah S1, Vijay MC2, Lijo James3
Padmavathi College of Pharmacy and Research Institute, Krishnagiri Main road, Periyanahalli, Dharampuri, Tamilnadu, India
Adverse drug reaction (ADR) is an unintended and unexpected effect can be caused by many drugs; this definition is differing by the side effect. It is fourth leading cause of death in developed western countries and sixth leading cause of death in the world. An adverse drug reaction (ADRs) shows an important public health problem in animals, human beings and the environment which include less efficacy of drug, sensitivity like reactions. Pharmacovigilance is associated in the field of ADRs study. At present Cancer is the second leading cause of death globally, and was responsible for 8.8 million deaths in 2015. Globally, nearly 1 in 6 deaths is due to cancer uncontrolled growth of cells is called cancer. Cancer cells are also referred to as tumours or neoplasms. It is a heterogeneous group of diseases caused by the impairment of normal functioning of genes, which leads to genetic damage. Many treatment options for cancer exist with the primary ones including surgery, chemotherapy, radiation therapy and palliative care. These treatments are used depending upon the type, location and grade of the cancer. The most common medications affect mainly the fast-dividing cells of the body, such as blood cells and the cells lining the mouth, stomach, and intestines. Along with other oncology clinicians, intervention played by Clinical Pharmacist is vital and can therapeutically minimize, assess, monitor and manage ADRs of ANAs. Clinical Pharmacist should inform the clinicians about these adverse reactions during each administration time.
Adverse drug reaction, Pharmaco-vigilance, chemotherapy, Clinical Intervention, Anti-neoplastic agent>
Full Text Article
Call of Papers
Submit your article For 4th Issue on May 2018
Publish : 20-May-2018
JMPAS got approval of DOI (digital object identifier) and international plagarism clearance crtificate. and now we inviting all Dear Author/Researcher, Journal of Medical Pharmaceuticals and Allied Sciences (JMPAS) invites you to submit your research paper for publishing in Volume 7, Issue 4 (May 2018). Scope & Topics: Journal of Medical Pharmaceuticals and Allied Sciences (JMPAS) is a open access journal that publishes articles which contribute best results in all areas of the Medical, Pharmaceuticals and Allied Sciences.